PRAME expression stratifies treatment response in NSCLC histologies

PRAME expression predicts opposing treatment outcomes in LUSC vs. LUAD lung cancer

INDICATION
Lung
BIOMARKER
PRAME

High PRAME-LUSC expressors exhibit better survival after IO+Chemo in a 1L setting

 

 

Kaplan-Meier curves for real-world overall survival (rwOS) in NSCLC patients treated with immunotherapy (IO) and chemotherapy (Chemo) in combination or as monotherapies in the first-line (1L) setting in high PRAME-LUSC expressors (no trend). Survival differences between treatment groups were evaluated using the log-rank test (p=0.032).

 

Related cases

Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Grid displaying data points with blue, black, and gray squares on a white background.

RB1 loss-of-function mutations in post-Osimertinib NSCLC and prognostic implications

2026-07-01
Lung
RB1
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Abstract grid of small blue, gray, black, and orange squares on a white background.

Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma

2026-07-01
Lung
PPM1D
Icon with three vertical bars and a circle, resembling a bar graph or LinkedIn logo.Lens Library
Pixelated diagonal gradient with bands of purple, blue, and green dots, resembling data visualization.

PRAME expression and histology impact survival in first-line NSCLC

2026-05-26
Lung
PRAME